The study was not set up to look at any differences between the two. The Pfizer/BioNTech was available first so there is more data, but the Oxford/AstraZeneca was mostly used in the older age group. These results are very encouraging and have given us great reasons to be optimistic for the future, said Professor Aziz Sheikh, director of the University of Edinburghs Usher Institute. The numbers were very small and there was uncertainty over their significance, said the researchers. It is an important point but we cant at the moment say anything about that, he said.
Pfizer and his group did a separate study of unobstructed fetal alcohol syndrome.
( z0 do :ARG0 ( z1 and :op ( z2 person :name ( z3 name :op "Pfizer" ) ) :op ( z4 group :poss z2 ) ) :ARG1 ( z5 study :ARG1 ( z6 syndrome :ARG1-of ( z7 obstruct :polarity - ) :mod ( z8 alcohol ) ) :ARG1-of ( z9 separate ) ) :rel ( z10 fetal ) )
(z0 / do-02
    :ARG0 (z1 / and
              :op1 (z2 / person
                       :name (z3 / name
                                 :op1 "Pfizer"))
              :op2 (z4 / group
                       :poss z2))
    :ARG1 (z5 / study-01
              :ARG1 (z6 / syndrome
                        :ARG1-of (z7 / obstruct-01
                                     :polarity -)
                        :mod (z8 / alcohol))
              :ARG1-of (z9 / separate-02))
    :rel (z10 / fetal))
Pfizer and his group did a separate study of unobstructed fetal alcohol syndrome .
z2 :name z3
z3 :op1 1
z1 :op1 z2
z1 :op2 z4
z4 :poss z2
z0 :ARG0 z1
z5 :ARG1-of z9
z0 :ARG1 z5
z7 :polarity 0
z6 :mod z8
z6 :ARG1-of z7
z5 :ARG1 z6
z0 :rel z10